Positron Emission Tomography Market Overview
The global Positron Emission Tomography (PET) market is projected to grow at approximately 5% over the next five years. Increasing prevalence of cancer and neurological and cardiovascular disorders, advancements in PET imaging systems and radiopharmaceuticals, growing demand for early and accurate disease detection, expanding clinical applications, and rising investments in healthcare infrastructure are supporting market expansion.
Positron Emission Tomography is an advanced nuclear medicine imaging technology used to visualize physiological and metabolic activity within the body. Unlike conventional anatomical imaging techniques such as CT and MRI, PET provides functional information by tracking metabolic processes, including glucose utilization, oxygen consumption, and blood flow. This capability makes PET particularly valuable for detecting abnormalities at an early stage and evaluating disease progression and treatment response.
The rising incidence of cancer, coronary artery disease, Alzheimer’s disease, Parkinson’s disease, and epilepsy is increasing the need for advanced functional imaging. PET is widely used in oncology for cancer detection, staging, treatment planning, and monitoring therapeutic response. Its growing role in neurological imaging and cardiac assessment is also creating additional opportunities for market growth.
The increasing volume of PET and PET/CT procedures across developed healthcare systems highlights the expanding clinical utilization of the technology. According to NHS England estimates, approximately 180,000 PET-CT scans are performed annually in the U.K. Growing procedure volumes, combined with improvements in diagnostic infrastructure, are expected to support demand for PET systems and associated radiopharmaceuticals.
Rising healthcare expenditure and improvements in medical infrastructure are further facilitating the adoption of advanced imaging technologies. Favorable reimbursement policies for diagnostic imaging in several markets are helping healthcare providers invest in modern PET equipment. At the same time, manufacturers are pursuing product launches, collaborations, and technology development to strengthen their competitive positions.
The development of portable and mobile PET solutions could further increase accessibility to advanced imaging. Such systems may enable healthcare providers to deliver PET services across facilities with limited access to conventional nuclear imaging infrastructure, including smaller hospitals and underserved regions.
The COVID-19 pandemic temporarily disrupted the PET market as lockdowns, hospital capacity constraints, and delays in non-emergency procedures resulted in the postponement or cancellation of several imaging examinations. PET procedure volumes declined significantly during 2020. However, diagnostic activity gradually recovered from 2021 as healthcare services resumed and delayed procedures were performed, supporting the market’s return to steady growth.
Key Request a free sample copy or view report summary: https://meditechinsights.com/global-positron-emission-tomography-pet-market/request-sample/
Technological Advancements in PET Imaging
Technological innovation remains a major factor shaping the PET market. The integration of PET with CT and MRI has resulted in hybrid imaging platforms capable of providing complementary functional and anatomical information during a single examination. PET/CT has become particularly important in oncology because it can help clinicians identify lesions, determine disease extent, and support treatment planning.
Total-body PET systems represent another important area of innovation. These systems are designed to capture signals across a much larger portion of the body simultaneously, potentially improving imaging efficiency and enabling dynamic assessment of tracer distribution throughout the body. In July 2021, GE Healthcare collaborated with Quibim on the development of a total-body PET/CT scanner, highlighting the industry’s focus on advanced whole-body imaging capabilities.
Time-of-flight PET technology is also contributing to improvements in imaging performance. By estimating the difference in photon arrival times at detectors, time-of-flight techniques can improve localization of radioactive signals, enhance image quality, and potentially reduce scan duration. These benefits can improve workflow efficiency and patient experience.
The transition from analog to digital PET detectors is another significant development. Digital detector technologies can provide better sensitivity and image quality while supporting shorter acquisition times and potentially reducing radiation exposure. Increasing availability of digital PET systems is therefore expected to encourage technology upgrades across healthcare facilities.
Growing Importance of Radiopharmaceuticals
The expansion of PET imaging is closely linked to advances in radiopharmaceuticals and radiotracers. PET relies on radioactive tracers to identify specific biological processes, allowing physicians to visualize metabolic and molecular activity that may not be apparent through anatomical imaging alone.
The growing burden of cancer and other chronic diseases is increasing demand for PET-based diagnostic and treatment-monitoring applications. At the same time, the development of new radioisotopes and disease-specific tracers is broadening the clinical utility of PET.
Novel radiopharmaceuticals targeting cancer biomarkers, neurological conditions, and cardiovascular processes are creating opportunities for more precise imaging. Improvements in tracer availability and production are also expected to support wider adoption of PET analysis in clinical research and routine diagnosis.
Positron Emission Tomography Market Trends
The integration of PET and CT remains a major market trend as healthcare providers seek imaging solutions that combine functional and anatomical information in one examination.
PET applications in cardiac imaging are expanding, particularly in myocardial perfusion assessment and evaluation of myocardial viability. The high diagnostic performance of PET is supporting its use in cardiovascular disease evaluation.
Disease-specific radiopharmaceuticals and novel molecular tracers are broadening PET applications across oncology, neurology, and cardiology.
Digital PET detector adoption is increasing as healthcare providers seek improved image quality, faster examinations, greater sensitivity, and optimized radiation exposure.
Artificial intelligence is increasingly being incorporated into PET workflows for image reconstruction, segmentation, quantitative analysis, and interpretation. AI-based technologies can help enhance image quality, streamline workflows, and support clinical decision-making.
Mobile and portable PET services are emerging as potential solutions for improving access to advanced imaging in remote and underserved locations.
Radiation dose optimization continues to be a priority for manufacturers and healthcare providers. New acquisition technologies, reconstruction methods, and imaging protocols are being developed to maintain diagnostic quality while minimizing patient exposure.
Oncology remains one of the most important application areas for PET. Increasing use in cancer detection, staging, recurrence assessment, treatment planning, and therapy monitoring is expected to sustain demand for PET systems and radiopharmaceuticals.
Positron Emission Tomography Market Competitive Landscape
The PET market is characterized by the presence of established medical imaging companies and specialized technology providers. Leading participants are investing in research and development to improve detector technology, image reconstruction, diagnostic accuracy, workflow efficiency, and patient safety.
Strategic collaborations and technology partnerships are becoming important competitive strategies as companies seek to combine imaging hardware with artificial intelligence, software, radiopharmaceutical expertise, and advanced analytics. Companies are also expanding their geographic presence to capture growing demand in emerging healthcare markets.
Product development is increasingly focused on integrated imaging platforms, including PET/CT and PET/MRI systems, as well as digital and total-body PET technologies. Mergers, acquisitions, partnerships, and portfolio expansion are also being used to strengthen technological capabilities and market reach.
The growing emphasis on cost-effective imaging solutions may further influence competition, particularly in developing markets where healthcare providers are seeking advanced diagnostic capabilities while managing capital expenditure.
Key Players in the Positron Emission Tomography Market
- Canon Medical Systems Corporation
- CMR Naviscan
- Fujifilm Holdings Corporation
- GE Healthcare
- Koninklijke Philips
- Mediso
- Minfound Medical Systems
- Molecubes
- Neusoft Corporation
- Oncovision
- Positron
- Radialis
- Siemens Healthineers
- Toshiba International Corporation
- Yangzhou Kindsway Biotech
Future Outlook
The Positron Emission Tomography market is expected to maintain steady growth as healthcare systems increasingly prioritize early diagnosis, precision medicine, and personalized treatment. Continued advances in PET/CT and PET/MRI, digital detector technologies, total-body imaging, AI-powered image analysis, and radiopharmaceutical development are likely to expand the technology’s clinical applications.
The increasing global burden of cancer, cardiovascular diseases, and neurological disorders will remain an important source of demand. Meanwhile, improvements in healthcare infrastructure, reimbursement, research funding, and the availability of innovative PET technologies are expected to support adoption across developed and emerging markets.
Key Request a free sample copy or view report summary: https://meditechinsights.com/global-positron-emission-tomography-pet-market/request-sample/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
